Latest Biologic Stories
Catalent’s Zydis® Technology Used to Develop Thermo Stable and Cold-Chain Independent Vaccines Somerset, NJ (PRWEB) April 20, 2015 Catalent, the
INDIANAPOLIS, April 20, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the investigational medicine ixekizumab was statistically superior to placebo in the treatment
Biosimilars Council Releases First Biosimilars Handbook for U.S.
PORTLAND, Oregon, April 16, 2015 /PRNewswire/ -- A new report by Allied Market Research, titled, "Global Intravenous Immunoglobulin (IVIG) Market - Size, Industry Analysis,
Disability Community Calls for Consumer Safeguards and Guidance from FDA for New Category of Biologic Drugs WASHINGTON, April 16, 2015 /PRNewswire-USNewswire/ --
BEIJING, April 16, 2015 /PRNewswire/ -- China Biologic Products, Inc.
OXFORD, England, April 16, 2015 /PRNewswire/ -- Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer and other diseases,
CRANBURY, N.J., April 15, 2015 /PRNewswire/ -- Oncobiologics, Inc., a biotherapeutics company focused on developing and commercializing biosimilars, today announced that clinical development
Catalent Pharma Solutions (Booth 1546), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced
LAKE FOREST, Ill., April 13, 2015 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and
- Growing in low tufty patches.